Published in Neurobiol Dis on May 31, 2010
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Serotonergic dysfunction in the A53T alpha-synuclein mouse model of Parkinson's disease. J Neurochem (2015) 1.51
Improving response inhibition systems in frontotemporal dementia with citalopram. Brain (2015) 1.12
Clinical application of stem cell therapy in Parkinson's disease. BMC Med (2012) 1.07
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. Lancet (2014) 1.00
Noradrenaline and Parkinson's disease. Front Syst Neurosci (2011) 0.94
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications. Front Neurol (2014) 0.92
Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? BMC Med (2010) 0.91
Improving response inhibition in Parkinson's disease with atomoxetine. Biol Psychiatry (2014) 0.91
Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease. Brain (2014) 0.89
Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology (2013) 0.87
Multiple modes of impulsivity in Parkinson's disease. PLoS One (2014) 0.87
The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res (2013) 0.86
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. J Neurochem (2011) 0.86
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. Neurosci Biobehav Rev (2014) 0.86
Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal (2011) 0.85
Positron emission tomography neuroimaging in Parkinson's disease. Am J Transl Res (2011) 0.85
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord (2014) 0.85
Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front Neural Circuits (2014) 0.84
Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease. Neurobiol Dis (2013) 0.84
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med (2013) 0.82
Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. PLoS One (2014) 0.82
Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia. Parkinsons Dis (2011) 0.82
The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats. Br J Pharmacol (2016) 0.81
Recent imaging advances in neurology. J Neurol (2015) 0.81
The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study. PLoS One (2012) 0.80
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures. Hum Brain Mapp (2016) 0.79
Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci (2013) 0.79
Transcranial midbrain sonography and depressive symptoms in patients with Parkinson's disease. J Neurol (2015) 0.79
Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. Arch Neurol (2012) 0.78
Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Exp Neurol (2015) 0.77
Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinson's Disease. Front Neurol (2015) 0.77
Positron emission tomography imaging in neurological disorders. J Neurol (2012) 0.77
Parkinson's: a syndrome rather than a disease? J Neural Transm (Vienna) (2016) 0.76
Critical aspects of clinical trial design for novel cell and gene therapies. Parkinsons Dis (2011) 0.76
A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Mov Disord (2015) 0.75
Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. Front Cell Neurosci (2016) 0.75
The pons and human affective processing - Implications for Parkinson's disease. EBioMedicine (2015) 0.75
Recent progress of imaging agents for Parkinson's disease. Curr Neuropharmacol (2014) 0.75
SERT-to-DAT ratios in early Parkinson's disease do not correlate with the development of dyskinesias. EJNMMI Res (2013) 0.75
Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats. Rejuvenation Res (2015) 0.75
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis? NPJ Parkinsons Dis (2017) 0.75
Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. J Neurol (2015) 0.75
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp (2003) 4.34
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol (2011) 3.42
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol (2012) 2.75
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis (2005) 2.59
Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 2.56
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis (2008) 2.27
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord (2009) 1.90
Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol (2006) 1.81
Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med (2010) 1.78
Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol (2008) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med (2007) 1.76
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol Dis (2007) 1.69
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med (2009) 1.65
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology (2012) 1.63
The human premotor cortex is 'mirror' only for biological actions. Curr Biol (2004) 1.59
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res (2002) 1.55
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One (2013) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol (2002) 1.51
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med (2005) 1.49
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol (2010) 1.47
Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain (2008) 1.45
Parkinson's disease symptoms: the patient's perspective. Mov Disord (2010) 1.40
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain (2002) 1.30
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Chorea associated with thyroxine replacement therapy. Mov Disord (2005) 1.23
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord (2006) 1.22
Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain (2011) 1.22
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain (2010) 1.17
Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain (2010) 1.17
Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus. Neuroimage (2007) 1.17
Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp (2002) 1.17
Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain (2004) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. Neuropsychologia (2006) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol (2003) 1.13
Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage (2012) 1.13
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord (2006) 1.13
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain (2011) 1.11
Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease. J Nucl Med (2008) 1.10
Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol (2003) 1.10
GABAergic dysfunction in essential tremor: an 11C-flumazenil PET study. J Nucl Med (2010) 1.09
Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry (2006) 1.08
Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol (2012) 1.05
Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. Brain (2013) 1.05
Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS (2014) 1.04
Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. Neuroimage (2011) 1.03
Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta (2008) 1.03
Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain (2003) 1.03